ADVANCELL is a Spanish biotechnology company focused on the development of drug candidates with significant commercial potential in oncology, dermatology and neurology indications.
The company creates new product opportunities by leveraging an innovative nanosystems technology and by in-licensing promising projects at a pre-clinical stage.
ADVANCELL is also open to approaches from parties interested in collaboration.
ADVANCELL has several programmes in clinical development and pursues a series of preclinical opportunities, both proprietary and in collaboration.
The company’s headquarters are located in the Barcelona Science Park (PCB), while its nanosystems laboratory is in Santiago de Compostela, Spain.
ADVANCELL has developed the proprietary and patent-protected Dermosome Technology® to formulate and reformulate drug candidates that have been identified internally or in collaboration with its partners.
The company’s technology utilises polysaccharides and other excipients to generate nanosystems that confer new properties the active ingredient, creating nanomedicines that will result in benefits to patients such as increased efficacy, better safety, or more convenient dosing.
Based on the properties of its technology, ADVANCELL’s nanosystems are suitable for formulating small molecule drugs, proteins, peptides, antibodies or antibody fragments and nucleic acids for dermal or mucosal delivery.
Baldiri Reixac 10-12
Phone: +34 934 034 545
Fax: +34 934 034 544